Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Kazakhstan Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT07593196 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07593196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07593196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Kazakhstan Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
June 12, 2026
Completion date
December 31, 2026
Enrollment
240 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer